¦~»´¿}§¿¯fªº¶EÂ_¡B¤ÀÃþ¤Î¬y¦æ¯f¾ÇÁͶÕ

Ĭ´º³Ç¡BùºÖªQÂå®v

¿}§¿¯f¬O¤@¸s¥NÁ²§±`¯e¯f¡A¯S¼x¬O°ª¦å¿}¡A°_¦]©ó¯Ø®q¯À¤Àªc©Î§@¥Î¯Ê·l©Ò¾É­P¡Cªø´ÁºC©Êªº°ª¦å¿}·|¾É­P²´·ú¡BµÇŦ¡B¯«¸g¡B¤ßŦ¤Î¦åºÞµ¥¾¹©x¨ü·l¡B¥\¯à¤£¨}¬Æ¦Ü°IºÜ¡C

¿}§¿¯fªº¤ÀÃþ¦³«Ü¦h¡A¥]¬A²Ä1«¬¡B²Ä2«¬¿}§¿¯f¡B£]-²Ó­M¥\¯à¿ò¶Ç¯Ê·l¡B¯Ø®q¯À§@¥Î¿ò¶Ç¯Ê·l¡B¯ØŦ¯e±w¡B¤º¤Àªc¯e±w¡BÃĪ«©Î¤Æ¾Ç«~¤Þ°_ªÌ¡B¯Ø®q¯À±µ¨ü¾¹²§±`¡B¬Y¨Ç¿ò¶Ç¯e¯f¤Î·P¬V¡B§³®W¿}§¿¯fµ¥[¨£ªí1]¡C

ªí1¡B¿}§¿¯fªº¤ÀÃþ

²Ä1«¬¿}§¿¯f
¦ÛÅé§K¬Ì¤Þ°_
¯Sµo©Ê
²Ä2«¬¿}§¿¯f
§³®W«¬¿}§¿¯f
¨ä¥L¯S®í«¬

£]-²Ó­M¥\¯à¿ò¶Ç¯Ê·l

    ¦p¦~«C¤H¦¨¦~«¬¿}§¿¯f(maturity onset diabetes of the young, MODY)¡B²É¸¢ÅéDNAµ¥

¯Ø®q¯À§@¥Î¿ò¶Ç¯Ê·l    

    ¦pA«¬¯Ø®q¯Àªý§Ü¡BLeprechaunismµ¥

¯ØŦ¯e±w    

  

    ¦p¯ØŦª¢¡B¯ØŦ¥~¶Ë¡B¯ØŦ¸~½Fµ¥

¤º¤Àªc¯e±w

   ¦p¥Òª¬¸¢°ª¯à¯g¡BAcromegaly¡B®wªY¤ó¯g¡B¶Ý»Ì²Ó­M½Fµ¥

ÃĪ«©Î¤Æ¾ÇÃÄ«~¤Þ°_

    ¦pVacor¡BPentamidine¡BNicotinic acid¡BGlucocorticoidsµ¥

·P¬V¤Þ°_

   

    ¦p¥ý¤Ñ©Ê¼w°ê·ò¯l¡B¥¨²Ó­M¯f¬rµ¥

¤£±`¨£§K¬Ì¤Þ°_¯e±w¦p¡§Stiff-man¡¨¯g­Ô¸s

n              

¨ä¥L¿ò¶Ç¯g­Ô¸s¦³®É¦X¨Ö¿}§¿¯f

    ¦pPrader Willi¯g­Ô¸s¡BTurne¯g­Ô¸sµ¥

¿}§¿¯fªº¶EÂ_¼Ð·Ç

¤@¯ë¤HªºªÅ¸¡¦å¿}¤j¬ù¦b90mg/dl¥ª¥k¡A¶º«á¦å¿}µu¼È¤W¤É¡A¦ý«Ü¤Ö¶W¹L140mg/dl¡C¿}§¿¯fªº¶EÂ_¦³¥H¤U¤TºØ°ò·Ç¡G¤@¡B¥ô¦ó®É¶¡¦å¿}¶W¹L200mg/dl¥B¦³¿}§¿¯f¦h³Ü¡B¦h§¿¡BÅé­«¤U­°µ¥¯gª¬¡F¤G¡BªÅ¸¡8¤p®É¥H¤W¦å¿} ³ 126 mg/dl¡F¤T¡B¤fªA¸²µå¿}­@¶q¸ÕÅç(OGTT)«á¤G¤p®É¦å¿}³ 200 mg/dl¡A«h¬°¿}§¿¯f[¨£ªí2]¡C©Ò¿×¤fªA¸²µå¿}­@¶q¸ÕÅç(OGTT)¡A«h¬°¤­¤ÀÄÁ¤º¦¨¤H³Ü250-300²@¤É75¤½§J¸²µå¿}·»²G¡A¨àµ£«h¨C¤½¤çÅé­«1.75¤½§J( ³Ì¦h75¤½§J)¡AÀËÅçªÅ¸¡¡B30¤À¡B60¤À¡B90¤À¡B120ÄÁªº¦å¿}¡C

ªí2¡B¿}§¿¯fªº¶EÂ_¼Ð·Ç

1.      ¿}§¿¯f¯gª¬¥[¤W¦å¼ß¸²µå¿}¿@«× ¡Ù 200 mg/dl (¡Ù 11.1 mmol/l)

   ¿}§¿¯fªº¨å«¬¯gª¬¥]¬A¡G¦h§¿¡B¦h³Ü¡BÅé­«¤U­°

©Î

2.      ªÅ¸¡8¤p®É¥H¤W¦å¿} ¡Ù 126 mg/dl (¡Ù 7.0 mmol/l)

©Î

3. ¤fªA¸²µå¿}­@¶q¸ÕÅç(OGTT)«á¤G¤p®É¦å¿}¡Ù 200 mg/dl (¡Ù 11.1 mmol/l)

°ò·Ç2©M3À³¸Ó¦b¤À¹j¤é¤l­«½Æ´ú¸Õ¨Ó½T©w.

¥»ªí¨ú¦ÛAmerican Diabetes Association, 2004.

¦pªGªÅ¸¡¦å¿}§C©ó126mg/dl¡B°ª©ó100mg/l¡A«h¬°ªÅ¸¡¦å¿}²§±`(IFG)¡F­Y¤fªA­@¿}¸ÕÅç(OGTT)«á¤G¤p®É¦å¿}¤¶©ó140-199mg/dl¡A«h¬°¸²µå¿}­@©Ê²§±`(impaired glucose tolerance,IGT)[¨£ªí2]¡C­Y¬O¦³ªÅ¸¡¦å¿}²§±`©Î¸²µå¿}­@©Ê²§±`¡A¥i¹w´ú¥¼¨Ó¼Æ¦~«á·|µo®i¦¨¿}§¿¯f¡A»Ý­n¿n·¥§ïÅܥͬ¡¤è¦¡¡]¦p¹B°Ê¡B¤£³Ü§t¿}¶¼®Æµ¥¡^¨Ó©µ½wµo®i¦¨¿}§¿¯f¡C

ªí3¡B¸²µå¿}­@¨ü¤ÀÃþ

ªÅ¸¡¦å¿}

¤fªA¸²µå¿}­@¶q¸ÕÅç(OGTT)«á¤G¤p®É¦å¿}

¥¿±`¡G< 100 mg/dl (<5.6 mmol/l)

¥¿±`¡G< 140 mg/dl (<7.8 mmol/l)

ªÅ¸¡¦å¿}²§±`¡G¡Ù100 mg/dl (¡Ù5.6 mmol/l) ¤Î <126 mg/dl (<7.0 mmol/l)

¸²µå¿}­@¨ü²§±`¡G¡Ù140 mg/dl (¡Ù7.8 mmol/l) ¤Î <200 mg/dl (<11.1 mmol/l)

¿}§¿¯f¡G¡Ù126 mg/dl (¡Ù7.0 mmol/l)

¿}§¿¯f¡G¡Ù200 mg/dl (¡Ù11.1 mmol/l)

¥»ªí¨ú¦ÛAmerican Diabetes Association, 2004.

¦~»´¿}§¿¯fªº¯S½è¤Î¬y¦æ¯f¾ÇÁͶÕ

²Ä1«¬¿}§¿¯f¡]type 1 diabetes¡^

¨àµ£¤Î«C¤Ö¦~©Ò±o¨ìªº¿}§¿¯f¥D­n¬O²Ä1«¬¿}§¿¯f¡C¥þ¥@¬É¤£¦Pªº°ê®a¦³µÛ§¹¥þ¤£¦Pªºµo¥Í²v¡A¨Ò¦p¬ü°ê2002¦~ªº½Õ¬d¡Aµo¥Í²v¬ù¬O¤Q¸U¤À¤§20¡A²±¦æ²v¬ù¬O0.25%¡A¥ç§Y20·³¥H¤Uªº¾ÇÄ֨ൣ¤Î«C¤Ö¦~¤¤¬ù¦³206,000¤H¦³¿}§¿¯f¡A¤]´N¬O»¡20·³¥H¤U¨C400-500¤H¤¤´N¦³¤@¤H¬O¿}§¿¯f¡CªâÄõªº¨àµ£±o¨ì²Ä1«¬¿}§¿¯fªº¾÷·|(¤Q¸U¤À¤§40)¬O¤é¥»¨àµ£ªº±Nªñ40­¿¡A¬Æ¦Ü¬O¤¤°ê¶Q¦{¿í¸qªº100­¿(¤Q¸U¤À¤§0.1)[Devendra D, 2004 ]¡C°£¦¹¤§¥~¡A²Ä1«¬¿}§¿¯fªºµo¥Í²vªñ´X¦~¨Ó¤]¦³¦¨ªøªºÁͶաC®Ú¾Ú¼Ú¬wªº³ø§i¡A²Ä1«¬¿}§¿¯fªº¨C¦~ªºµo¥Í²v¦¨ªø¬ù¬°3-4%¡A¨ä¤¤0-4·³ªº¦¨ªø²v¼W¥[³Ì¦h¡A¬°6.3%¡A5-9·³¬°3.1%¡A10-14·³¬°2.4%¡A¦ô­p¨ì2010¦~²Ä1«¬¿}§¿¯fªºµo¥Í²v·|¤ñ1997·|¼W¥[40%¡C[Atkinson MA, 2001]

²Ä1«¬¿}§¿¯f¡]type 1 diabetes¡^ªº¯S¼x¬°¯Ø®q£]-²Ó­M³Q¯}Ãa¾É­Pµ´¹ï¯Ø®q¯À¯Ê¥F¡A¥H«e³QºÙ¬°¯Ø®q¯À¨Ì¿à«¬¿}§¿¯f¡]insulin dependent diabetes mellitus, IDDM¡^¡A¦b©Ò¦³¿}§¿¯f¤H¤¤¬ù¦û5-10%¡C¦¹«¬¯f¤H£]-²Ó­M¤j³¡¤À¬°¦ÛÅé§K¬Ì¯}Ãa¡A¬ù90%«D¦è¯Z¤ú¸Çªº¥ÕºØ¤H¡B50%¦è¯Z¤ú¸Ç¤Î«D¬w¸Çªº¥ÕºØ¤H¡B88%¥xÆW¨àµ£Äݩ󦹺ئÛÅé§K¬Ì«¬[Lo FS, 2004]¡A¥i¥H±q¦å²G¤¤Åç¥X¯}Ãa¯Ø®q²Ó­Mªº¦ÛÅé§ÜÅé¦pislet²Ó­M§ÜÅé¡]ICA¡^¡Binsulin autoantiboies¡]IAA¡^¡BGAD65§ÜÅéµ¥¡A¦¹«¬¯f¤H»PHLAÃöÁp©Ê±j¡F¨ä¾l¯f¤HÄÝ©ó¦Ûµo©Ê¡]idiopathic¡^¡A¥ç§Y¤£©ú­ì¦]³y¦¨¥Ã¤[¯Ø®q¯À¯Ê¥F¡A©ö³y¦¨à¬»Ä¤¤¬r¡C³Ì«á¡A²Ä1«¬¿}§¿¯f¤H¦b¥xÆW¨É¦³°·«O¡u­«¤j¶Ë¯f¡vªº¸ê®æ¡A¬Ý¶E®É¥i¬Ù¥h³¡¤À¤À¾áªº¶O¥Î¡C

²Ä2«¬¿}§¿¯f¡]type 2 diabetes¡^

ªñ¤G¤Q¦~¤£½×¬O¦b¬ü°ê©Î¬O¼Ú¬w¡A¦³·U¨Ó·U¦h¨àµ£¤Î«C¤Ö¦~¿©±w¶Ç²Î¤W³Q»{¬°¬O40·³¥H¤W¤~·|±o¨ìªº²Ä2«¬¿}§¿¯f¡C¦b¬ü°ê¡A¦³¤@¨Ç³ø§i«ü¥X¦b·sµo¥Íªº¨àµ£¿}§¿¯f¤¤¡A¤w¦³¬ù8-45%¨Ã¤£¬O²Ä1«¬¿}§¿¯f¡A¦Ó¬O²Ä2«¬¿}§¿¯f¡C¦b¨È¬w¡A±q¤é¥»ªF¨Ê°ê¤¤¥Íªº½Õ¬d¤¤µo²{¡A²Ä2«¬¿}§¿¯fªº²±¦æ²v¤]±q1976-1980¦~ªº¤Q¸U¤À¤§7.3¡A³vº¥¤W¤É¦Ü1981-1995¦~ªº¤Q¸U¤À¤§12.1¤Î1991-1995ªº¤Q¸U¤À¤§13.9 [Kitagawa T, 1998]¡C¦Ó¦b¥xÆW¡A®Ú¾Ú¥x¤j²ø¥ß¥Á±Ð±Â¦b1992¦Ü1999¦~¦b¥þ¥xÆW©Ò§@ªº¤¤¤p¾Ç¥Íªº¥þ­±´¶¬d¬ã¨s[Wei JN, 2003]¡A¦b6-18·³ªº¨àµ£¤Î«C¤Ö¦~¤¤¡A·s¶EÂ_¿}§¿¯fªºµo¥Í²v¬ù¬O¤Q¸U¤À¤§12¡A¨ä¤¤¤k¥Í¤j©ó¨k¥Í(10¸U¤À¤§15.3¤ñ10¸U¤À¤§9.0)¡C³o¨ä¤¤9.5%¬O²Ä1«¬¿}§¿¯f¡A¦Ó²Ä2«¬¿}§¿¯f«h¬O54.2%¡A¥t¥~8.7%«h¬O¦¸µo«¬¿}§¿¯f¡]«üªº¬O¦]¨ä¥L¦]¯À¦Ó¤Þ°_ªº¿}§¿¯f¡A¨Ò¦p¦]¬õ´³©Ê¯T½H¥²¶·ªA¥ÎÃþ©T¾J¦Ó³y¦¨ªº¦å¿}¤W¤É¡^¡C¤]´N¬O»¡¦b³o­Ó¦~ÄÖ¼h¡A²Ä1«¬¿}§¿¯fªºµo¥Í²v¬ù¬°¤Q¸U¤À¤§1.1¡A¦Ó²Ä2«¬¿}§¿¯f«h¬°¤Q¸U¤À¤§6.5¡C

²Ä2«¬¿}§¿¯f¡]type 2 diabetes¡^ªº¯S¼x¬°¯Ø®q¯Àªý§Ü¦X¨Ö¬Û¹ïªº¯Ø®q¯À¯Ê¥F¡A¥H«e³QºÙ¬°«D¯Ø®q¯À¨Ì¿à«¬¿}§¿¯f¡]non-insulin dependent diabetes mellitus, NIDDM¡^¡A¦b©Ò¦³¿}§¿¯f¤H¤¤¬ù¦û90-95%¡C¦¹«¬¯f¤H¯f¦]¤£©ú¡A¦ý¬O¤j³¡¤À¯f¤HÅéºAªÎ­D¡B¦~¬ö°¾¤j¡BÀV¶µ¤ÎµÅ¤U¦³¶Â´Æ¥Ö¯g (Acanthosis nigricans)¡B±`¦³°ª¦åÀ£¡B°ª¦å¯×µ¥·s³¯¥NÁ¯g­Ô¸s¡]metabolic syndrome¡^¡B§C¥X¥ÍÅé­«¡B±`¦Y°ª¼ö¶q­¹ª«¤ÎÀRºA¬¡°Ê¦pªø®É¶¡¬Ý¹qµø¤Î¹q¸£¹CÀ¸µ¥¡C

¦~»´²Ä2«¬¿}§¿¯f¯fµ£³Q¶EÂ_ªº¦~ÄÖ¤]¤£Â_¦V¤U¡A¥Ø«e¶EÂ_ªº¥­§¡¦~ÄÖ¤w±µªñ«C¬K´Áªº¦~¬ö(¬ù12-14·³) [Fagot-Campagna A, 2000]¡C¦b¥xÆW²ø±Ð±Âªº°ê¤H¬ã¨s¤¤¤]µo²{¡A¦b10·³¥H¤U¡AÁÙ¬O¥H²Ä1«¬¿}§¿¯f¬°¥D¡A¦ý¦b11¨ì13·³¥H¤W¡A²Ä2«¬¿}§¿¯fªº¤ñ¨Ò¤w¶W¹L²Ä1«¬¤F¡C

¬°¤°»ò¯Ø®q¯Àªý§Ü©Ê·|¼W¥[¡HªÎ­D¥»¨­¬O¤@­Ó«Ü­«­nªº¦]¯À¡Cªñ¤G¤Q¦~¨Ó¡AªÎ­D²±¦æ²v¦b¥@¬É¦U°ê¤£Â_ªºª¦¤É©M¿}§¿¯fªºµo¥Í²v¼W¥[¡A¦ü¦³¤@­Pªº±¡§Î¡C±q1980¦~¥N¦Ü¤µ¡A¨àµ£ªÎ­Dªº±¡§Î¤w¼É¼W¤T­¿¡A®Ú¾Ú¬ü°ê¯e¯fºÞ¨î§½(CDC)¦b1999-2002¦~ªº½Õ¬d¡A6¨ì19·³ªº¬ü°ê¤H¦³16%(±Nªñ9¦Ê¸U¤H)¬O¹L­«ªº¡A»P1988-1994¦~ªº11%¬Û¤ñ¡A¼W¥[¤F45%¡C[Hedley AA, 2004]¦Ó¦b¥xÆW²ø±Ð±Âªº¬ã¨s¤]µo²{ªÎ­D¬O«Ü­«­nªº¦MÀI¦]¤l¡AªÎ­Dªº¤pªB¤Í±o¨ì²Ä2«¬¿}§¿¯fªº¾÷·|¬O¥¿±`Åé­«¤pªB¤Íªº18.8­¿¡C

¥t¥~¡A²Ä2«¬¿}§¿¯f¯fµ£³q±`¦³©úÅ㪺®a±Ú¥v¡A¾Ú¬ã¨s¬ù45-80%ªº¯f¤H¨ä¤÷¥À¿Ë¨ä¤@¦³¿}§¿¯f¡A¦Ó¦³74-100%ªº¯f¤H¨ä²Ä¤@µ¥¿Ë©Î²Ä¤Gµ¥¿Ë¬O¦³²Ä2«¬¿}§¿¯fªº¡A¦³¨Ç¬Æ¦Ü¼Æ¥N³£¥i°l·¹¨ì¿}§¿¯fªº®a±Ú¥v¡C¦Ó¦b¥xÆW²ø±Ð±Âªº¬ã¨s¤¤¤]µo²{¨ã¦³®a±Ú¥vªº«C¤Ö¦~±o²Ä2«¬¿}§¿¯fªº¦MÀI©Ê·|¼W¥[3.95­¿¡C­È±oª`·Nªº¬O¡A¦³®É­Ô¯fµ£¦b¶EÂ_¿}§¿¯f«á¡A¨ä®a±Ú¦¨­û¡A¦p¤÷¥À¡A¤~³Q¶EÂ_¥X¿}§¿¯f[ADA, 2000]¡C°£¦¹¤§¥~¡A¦b¬Y¨ÇºØ±Ú¡A¦p¬ü¸Ç¶Â¤H¡B©Ô¤B¬ü¬w¤H¡B¦L²Ä¦w¤H¤Î¤Ó¥­¬v¤@¨Ç®q°êªº­ì¦í¥Á¡A¬O¸û®e©ö±o¨ì¿}§¿¯fªº[Fagot-Campagna A, 2000]¡C¥t¥~¡A©Ê§O»P«C¬K´Á¦ü¥G¤]¦³©Ò¬ÛÃö¡C¤£½×¬O¦b°ê¥~©Î¬O¦b¥xÆW¡A³£µo²{¤k©Êªºµo¥Í²v³£°ª©ó¨k©Ê¡C¦¹¥~¡A¬ã¨s¤]µo²{¨àµ£ªº²Ä2«¬¿}§¿¯fªº¶EÂ_°ª®p´Á»P«C¬K´Á¬ù¦b¦P¤@®É´Á¡]12-16·³¡^¡C¬ã¨sµo²{¦b«C¬K´Á®É¥Ñ©ó¥Íªø¿E¯Àªº¼W¥[¡A¯Ø®q¯Àªºªý§Ü©Ê¤]·|¤ñ«C¬K´Á«e¨Ó±o¼W¥[¡A¹ï©ó¥»¨­¦]¿ò¶Ç¡]®a±Ú¥v¡^©ÎÀô¹Ò¡]ªÎ­D¡^ªº¦]¯À¦Ó¤w¦s¦b¯Ø®q¯Àªý§Ü©Êªº«C¤Ö¦~¡A£]²Ó­M©Ò¼W¥[ÄÀ©ñªº¯Ø®q¯À¤wµLªk¥­¿Å¼W¥[¤Ó¦hªº¯Ø®q¯Àªý§Ü©Ê¦Ó¨Ï±o¦å¿}·|¤W¤É¡C¦]¦¹¦p¦ó§ïÅܥͬ¡²ßºD¡A¤×¨ä¬O¶¼­¹©M¹B°Ê¡A¬O¹w¨¾¤ÎªvÀø²Ä2«¬¿}§¿¯f³Ì­«­nªº½ÒÃD¡C

¦~«C¤H¦¨¦~«¬¿}§¿¯f(maturity onset diabetes of the young, MODY)

¦¹Ãþªº¿}§¿¯f¨Ã¤£¦h¨£¡A¬O¤@¸s£]-²Ó­M¥\¯à³æ¤@°ò¦]¿ò¶Ç¯Ê·l©Ò³y¦¨ªº¯e¯f¡A¥i¥Hµo¥Í¦b¨àµ£¡B«C¤Ö¦~¡B¦~»´¤H¡]³q±`¦b25·³¥H«e¡^¡A¦ÛÅéÅã©Ê¿ò¶Ç¡A¥Ø«e¦³¤»­Ó¤£¦P¬V¦âÅé¿ò¶Ç§Ç¦C³Qµo²{¦p²Ä12¹ï¬V¦âÅ骺HNF-1(MODY3)¡B²Ä7¹ï¬V¦âÅ骺glucokinase (MODY2)¡B²Ä20¹ï¬V¦âÅ骺HNF-4 (MODY1)¡B²Ä13¹ï¬V¦âÅ骺insulin promoter factor-1 (IPF-1; MODY4)¡B²Ä17¹ï¬V¦âÅ骺HNF-1 (MODY5)¡B²Ä2¹ï¬V¦âÅ骺NeuroD1 (MODY6)¡A°£¤FMODY2¥~¡A¨ä¥L§¡¬OÂà¿ý¦]¤l¡A°Ñ»Pbeta²Ó­M¤¤¯S®í°ò¦]ªí²{ªº½Õ±±¡C¤@¥¹¦³°ÝÃD¡A«K·|¼vÅT¯Ø®q¯Àªº§Î¦¨»P¤Àªc¡C¦~«C¤H¦¨¦~«¬¿}§¿¯f¤¤¡A³Ì±`¨£ªº¬OMODY3¡A¥Ñ¨xŦÂà¿ý¦]¤l-1°ò¦]¡]hepatic transcription factor-1¡^¬ðÅܩҾɭP¡F²Ä¤G±`¨£¬°glucokinase (MODY2)¡C¦]¬°¦~«C¤H¦¨¦~«¬¿}§¿¯fÄÝ©ó³æ¤@°ò¦]¿ò¶Çªº¯e¯f¡A¬G¥¦ªº¶EÂ_»Ý­n¾a¤À¤l¿ò¶Ç§Þ³Nª½±µ°»´ú¬O§_¸Ó°ò¦]¬ðÅܨӶEÂ_¡C

Wolfram syndrome (DIDMOAD)

³o¬O¤@­Ó¦X¨Ö¤¤¼Ï©Ê§¿±Y¯g¡B¿}§¿¯f¡Bµø¯«¸gµäÁY¡B¦ÕŤªº¯g­Ô¸s¡A­ì¥ý¥H¬°¬OÄÝ©ó²É½uÅé¯e¯f¡A¦ý¬O³Ìªñµo²{¤j³¡¤À»P²Ä4¬V¦âÅé4p16.1ªºwolframin (WFS1)°ò¦]¬ðÅܦ³Ãö¡A¤]¦³³ø¾É»P²Ä4¬V¦âÅé4q22-q24ªº¦ì¸m¦³ÃöÁp¡C

¦~»´¿}§¿¯f¤ÀÃþªºÅ²§O¶EÂ_

²Ä1«¬¿}§¿¯f¡B²Ä2«¬¿}§¿¯f¡B¦~«C¤H¦¨¦~«¬¿}§¿¯f(maturity onset diabetes of the young, MODY)ªºÅ²§O¶EÂ_½Ð¨£¹Ï1¡Bªí4¡C ¦³¨Ç®É­Ô³o¤TÃþ¿}§¿¯f«ÜÃøŲ§O¶EÂ_¡A«o¤S«D±`­«­n¡A¦]¬°²o¯A¨ì¤@¶}©lªvÀø¬O¨Ï¥Î¯Ø®q¯Àª`®g¡BÁÙ¬O¤fªA­°¦å¿}ÃĪ«¡A½Ð°O±o¥ô¦ó«¬¿}§¿¯fªº´X¦~«áªº³Ì²×ªvÀø¤´ ¬O¯Ø®q¯Àª`®g¡A¥Ø¼Ð¬Oºû«ù¥¿±`¦å¿}¿@«×¡A´î¤Ö°ª¦å¿}±a¨ÓªººC©Ê¨Öµo¯g¡C­Y¬O§A¤@¶}©l¨Ï¥Î¤fªA­°¦å¿}ÃĪ«¡Aªù¶E°lÂܵo²{¦å¿}¨S§ïµ½¡B¿}¤Æ¦å¦â¯À¤´°ª©Î¨­°ªÅé ­«¨S¼W¥[¡A§A´N»Ý­n­«·sÀ˵ø§Aªº§PÂ_¡A¦Ò¼{¬I¥´¯Ø®q¯À¡F·íµM¡A®aÄݤίfµ£±`µLªk±µ¨ü¡A©Ò¥H»Ý­nªá®É¶¡·¾³q¡A´î¤Öªø´Á°ª¦å¿}±a¨ÓªººC©Ê¨Öµo¯g¡C

¤@¯ë¨Ó»¡¡A²Ä2«¬¿}§¿¯fªº«C¤Ö¦~¦Ü¤Ö¦~ÄÖ10·³¥H¤W¡BÅéºAªÎ­D¡BÀV¶µ¤ÎµÅ¤U¦³¶Â´Æ¥Ö¯g (Acanthosis nigricans)¡B±`¦ñ¦³°ª¦åÀ£¤Î°ª¦å¯×¡AµL¦ÛÅé§ÜÅé¡]¦pICA¡BIAA¡BGAD65§ÜÅéµ¥¡^¡BªÅ¸¡¯Ø®q¯À¤ÎC-peptide°ª¡]µ§ªÌ¸gÅçC-peptide¦Ü¤Ö2 ng/ml¥H¤W¡^¡A¦³®É»Ý­n¾a¤É¿}¯À¨ë¿E´úÅç¡]glucagon test¡^¬Ýc-peptideªº¦å²G¿@«×¡F¥t¥~²Ä2«¬¿}§¿¯fªº«C¤Ö¦~µo¯f®É¦³®É¤]¥i¥H଻Ĥ¤¬r¡]ketoacidosis¡^ªí²{¡Aµ¥¨ì¯f±¡Ã­©w¡B¦å¿}¿@«×¥¿±`«á¡A¹Á¸Õ´î¥b¯Ø®q¯À¾¯¶qÆ[¹î¤@¬P´Á¡A­Y¦å¿}¿@«×¤´µMºû«ù¥¿±`¡A¦A¹Á¸Õ´î¥b¯Ø®q¯À¾¯¶qÆ[¹î¤@¬P´Á¡F­Y¦å¿}¿@«×¤´µMºû«ù¥¿±`¡A¥i¥H¦Ò¼{§â¯Ø®q¯À°±±¼¡A¨Ï¥Î¤fªA­°¦å¿}ÃĪ«¡F­Y¦å¿}¿@«×°ª°_¨Ó¡A´NÄ~Äò¨Ï¥Î¯Ø®q¯À¡C

²Ä1«¬¿}§¿¯f¯f¤H¡A¦~¬ö¸û¤p¡]10·³¥H¤UÀu¥ý¦Ò¼{¦¹«¬¡^¡B¦ÛÅé§ÜÅ鶧©Ê¡B¤Ö¦³®a±Ú¥v¡B¦h¦]©Ê¿ò¶Ç¡B¤Ö¨£ªÎ­D¤Î¶Â´Æ¥Ö¯g¡BªÅ¸¡¯Ø®q¯À¤ÎC-peptide§C¡B±`¥H଻Ĥ¤¬rªí²{¡C

¹J¨ì¿}§¿¯f¤H®É»Ý­nª`·N¬O§_¥Ñ¤º¤Àªc¯e±w¦p¥Òª¬¸¢°ª¯à¯g¡B®wªY¤ó¯g¡]Cushing syndrome¡^¡B¶Ý»Ì²Ó­M½F¡]pheochromocytoma¡^µ¥¡A»Ý­n¶q¦åÀ£¡B´ú¤ß¸õ¡F­Y¤ß¸õ§Ö¡B¤â·|§Ý¡B¥Òª¬¸¢¸~¡A»Ý­n©â¦åÅç¥Òª¬¸¢¥\¯à¡F­Y¸G­D¡B¤ë«GÁy¡B¤ô¤ûªÓ¡B¸¡¥Ö¶²µ¥¡A¦Ò¼{®wªY¤ó¯g¡F­Y´c©Ê°ª¦åÀ£¤Î°}µo©ÊÀYµh¡A¦Ò¼{¶Ý»Ì²Ó­M½F¡C

¹Ï¤@¡B¦~»´¿}§¿¯f¤ÀÃþªºÅ²§O¶EÂ_·§­n

¨ú¦ÛADA: Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-389.

ªí4¡B²Ä1«¬¿}§¿¯f¡B²Ä2«¬¿}§¿¯f»P¦~«C¤H¦¨¦~«¬¿}§¿¯f¡]MODY¡^ªºÅ²§O¶EÂ_

 

²Ä1«¬¿}§¿¯f

²Ä2«¬¿}§¿¯f

¦~«C¤H¦¨¦~«¬¿}§¿¯f¡]MODY¡^

¦~ÄÖ

¨àµ£»P«C¤Ö¦~¡B¦~»´¦¨¤H¡]< 40·³¡^

«C¤Ö¦~¡]10·³¥H¤W¡^

¨àµ£¡B«C¤Ö¦~¡B¦~»´¤H¡]< 25·³¡^

¦ÛÅé§ÜÅé¦pICA¡BIAA¡BGAD65§ÜÅéµ¥

¶§©Ê

³±©Ê

³±©Ê

®a±Ú¥v

¤Ö¦³

±`¦³

¦ÛÅéÅã©Ê¿ò¶Ç

¿ò¶Ç

¦h¦]©Ê

¦h¦]©Ê

³æ¦]©Ê

ªÎ­D

¤Ö¨£

«Ü±`¨£

¤Ö¨£

¶Â´Æ¥Ö¯g

¤Ö¨£

«Ü±`¨£

¤Ö¨£

¥NÁ¯g­Ô¸s¦p°ª¦åÀ£¡B°ª¦å¯×µ¥

¤Ö¨£

«Ü±`¨£

¤Ö¨£

ªÅ¸¡©Î¦y®pC-peptide

§C

°ª

§C

଻Ĥ¤¬r

±`¨£

¤Ö¨£

¤Ö¨£

 

°Ñ¦Ò¤åÄm¡G

1.      American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27 (suppl 1): s5-s10.

2.      Eisenbarth GS. Genetic counseling for autoimmune type 1 diabetes. In: Lebovitz HE, eds. Therapy for diabetes mellitus and related disorders. 4th ed. American Diabetes Association. 2004: 8-19.

3.      Lo FS, Yang MH, Chang LY, Ou YC, Van YH. Clinical and laboratory features of type 1 diabetic children at initial diagnosis. Acta Pediatr Tw 2004; 45: 218-223.

4.      http://www.cdc.gov/diabetes/news/docs/010912.htm 2004

5.      Devasenan Devendra, Edwin Liu, George S Eisenbarth: Type 1 diabetes: recent developments. British Medical Journal 2004;328:750-754.

6.      Mark A Atkinson, George S Eisenbarth: Type 1 diabetes: new perspectives on disease pathogenesis and treatment. Lancet 2001;358:221-229

7.      Kitagawa T, Owada M, Urakami T, Yamauchi K: Increased incidence of non-insulin dependent diabetes mellitus among Japanese schoolchildren correlates with an increased intake of animal protein and fat. Clinical Pediatrics 1998;37:111-115.

8.      Wei JN, Sung FC, Lin CC, Lin RS, Chiang CC, Chuang LM.: National surveillance for type 2 diabetes mellitus in Taiwanese children. JAMA 2003;290:1345-1350.

9.      Fagot-Campagna A, Pettitt DJ, Engelgau MM, Burrows NR, Geiss LS, Valdez R, Beckles GL, Saaddine J, Gregg EW, Williamson DF, Narayan KM: Type 2 diabetes among North American children and adolescents: an epidemiologic review and a public health perspective. Journal of Pediatrics 2000;136:664-672.

10.   Caprio S, Tamborlane WV: Metabolic impact of obesity in childhood. Endocrinology & Metabolism Clinics of North America 28:731-747, 2004

11.  Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM: Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:2847-2850.

12.  ADA: Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-389.

13.  Fagot-Campagna A: Emergence of type 2 diabetes mellitus in children: epidemiological evidence. Journal of Pediatric Endocrinology & Metabolism 2000;13:1395-1402.

14.  Fajans SS, Bell GI, Polonsky KS. Mechanisms of disease: molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. NEJM 2001;345:971-980.

15.  Maldonado M, Hampe CS, Gaur LK, D¡¦Amico S, Iyer D, Hammerle LP, Bolgiano D, Rodriguez L, Rajan A, Lernmark A, Balasubramanyam A. Ketosis-prone diabetes: dissection of a heterogeneous syndrome using an immunogenetic and b-cell functional classification, prospective analysis, and clinical outcomes. J Clin Endocrinol Metab 2003;88: 5090¡V5098.